In HCC, the specific target of CVB‐D has not been identified, and only the inhibitory effect of CVB‐D on proliferation and metastasis has been reported, which may be related to the negative regulation of the EGFR‐FAK‐AKT/ERK1/2‐Slug signaling pathway [23]. Here, PTK2 is linked to hepatocellular carcinoma.